0 489

Cited 31 times in

Experimental studies on the antiviral agent famciclovir in Behçet's disease symptoms in ICR mice.

DC Field Value Language
dc.contributor.author방동식-
dc.date.accessioned2016-02-19T11:17:47Z-
dc.date.available2016-02-19T11:17:47Z-
dc.date.issued2001-
dc.identifier.issn0007-0963-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/142831-
dc.description.abstractBACKGROUND: Chronic oral aphthae, recurrent genital ulcers and uveitis are the three main manifestations of Behçet's disease (BD). The aetiopathogenesis of BD is still obscure, but herpes simplex virus (HSV) is one of the possible causal factors. Various kinds of drugs, including immunosuppressants and aciclovir have been used in treatment, but effectiveness is variable. OBJECTIVES: To demonstrate the efficacy of famciclovir, an antiviral compound that acts against HSV, varicella-zoster virus and hepatitis B virus, in a murine model of BD. METHODS: Using the HSV-induced BD mouse model, famciclovir was administered variously before and after inoculation or from the day of lesion occurrence, with appropriate controls. Ulceration of the mouth and genital skin and eye involvement were monitored. In addition, spleen cytokine expression was measured by polymerase chain reaction. RESULTS: Pretreatment and concurrent treatment did not affect the occurrence of BD, but treatment from the appearance of lesions was effective in improving BD and preventing recurrence. After famciclovir, interleukin 2 expression correlated with the recurrence of BD symptoms. CONCLUSIONS: This model suggests the possible role of immune response to viral infection in the development and activation of BD. The study provides a rationale for clinical trials of famciclovir in the human form of BD.-
dc.description.statementOfResponsibilityopen-
dc.format.extent799~804-
dc.relation.isPartOfBRITISH JOURNAL OF DERMATOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESH2-Aminopurine/analogs & derivatives*-
dc.subject.MESH2-Aminopurine/therapeutic use*-
dc.subject.MESHAnimals-
dc.subject.MESHAntiviral Agents/therapeutic use*-
dc.subject.MESHBehcet Syndrome/drug therapy*-
dc.subject.MESHBehcet Syndrome/immunology-
dc.subject.MESHBehcet Syndrome/virology-
dc.subject.MESHDisease Models, Animal-
dc.subject.MESHFamciclovir-
dc.subject.MESHHerpes Simplex/complications-
dc.subject.MESHHerpes Simplex/drug therapy-
dc.subject.MESHInterleukin-2/metabolism-
dc.subject.MESHMice-
dc.subject.MESHMice, Inbred ICR-
dc.subject.MESHProdrugs/therapeutic use*-
dc.subject.MESHRecurrence-
dc.subject.MESHReverse Transcriptase Polymerase Chain Reaction-
dc.titleExperimental studies on the antiviral agent famciclovir in Behçet's disease symptoms in ICR mice.-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Dermatology (피부과학)-
dc.contributor.googleauthorS. Sohn-
dc.contributor.googleauthorD. Bang-
dc.contributor.googleauthorE-S. Lee-
dc.contributor.googleauthorH.J. Kwon-
dc.contributor.googleauthorS.I. Lee-
dc.contributor.googleauthorS. Lee-
dc.identifier.doi10.1046/j.1365-2133.2001.04498.x-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA01784-
dc.relation.journalcodeJ00408-
dc.identifier.eissn1365-2133-
dc.identifier.pmid11736905-
dc.identifier.urlhttp://onlinelibrary.wiley.com/doi/10.1046/j.1365-2133.2001.04498.x/abstract-
dc.subject.keywordbehçet's disease-
dc.subject.keywordcytokine-
dc.subject.keywordfamciclovir-
dc.subject.keywordherpes simplex virus-
dc.contributor.alternativeNameBang, Dong Sik-
dc.contributor.affiliatedAuthorBang, Dong Sik-
dc.rights.accessRightsnot free-
dc.citation.volume145-
dc.citation.number5-
dc.citation.startPage799-
dc.citation.endPage804-
dc.identifier.bibliographicCitationBRITISH JOURNAL OF DERMATOLOGY, Vol.145(5) : 799-804, 2001-
dc.identifier.rimsid29884-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Dermatology (피부과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.